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Abstract
Background: A female/male (F/M) ratio increase over time in multiple sclerosis (MS) patients was demonstrated in many
countries around the world. So far, a direct comparison of sex ratio time-trends among MS populations from different
geographical areas was not carried out.
Objective: In this paper we assessed and compared sex ratio trends, over a 60-year span, in MS populations belonging to
different latitudinal areas.
Methods: Data of a cohort of 15,996 (F = 11,290; M= 4,706) definite MS with birth years ranging from 1930 to 1989 were
extracted from the international MSBase registry and the New Zealand MS database. Gender ratios were calculated by six
decades based on year of birth and were adjusted for the F/M born-alive ratio derived from the respective national registries
of births.
Results: Adjusted sex ratios showed a significant increase from the first to the last decade in the whole MS sample (from
2.35 to 2.73; p = 0.03) and in the subgroups belonging to the areas between 83u N and 45u N (from 1.93 to 4.55; p,0.0001)
and between 45u N to 35u N (from 1.46 to 2.30; p,0.05) latitude, while a sex ratio stability over time was found in the
subgroup from areas between 12u S and 55u S latitude. The sex ratio increase mainly affected relapsing-remitting (RR) MS.
Conclusions: Our results confirm a general sex ratio increase over time in RRMS and also demonstrate a latitudinal gradient
of this increase. These findings add useful information for planning case-control studies aimed to explore sex-related factors
responsible for MS development.
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Introduction
Multiple Sclerosis (MS) is a chronic demyelinating immune-
mediated disease of the Central Nervous System. The aetiology of
MS is subject to an extensive research effort and remains
undetermined. The importance of genetic factors in susceptibility
to MS is supported by several genetic epidemiological studies [1],
whereas migration studies, geographical gradients and disease
discordance in identical twins indicate that environmental factors
[2–3] could influence the development of MS, and that gene-
environment interactions may exert an even stronger effect. [4–5].
Recent meta-analyses [6] of epidemiological data have high-
lighted some relevant trends over the past few decades. A general
increase in the prevalence and incidence of MS, over time, was
demonstrated in many countries around the world, suggesting
that, whatever the causative factors of MS may be, their influence
appears to increase. A flattening of the latitudinal prevalence
gradient in MS in Europe and North America was found,
suggesting a gradual alteration of latitude-associated risk of MS.
[6–7] However results derived from data collected at different
times in distant regions and countries, are of major methodological
concern in regards to the variability in population size, compo-
sition, ethnic origin and age. Moreover, increasing frequency of
MS could be ascribed, at least partially, in some countries, to a
global improvement of case ascertainment, [7–8] diagnosis being
dependent on accessibility to adequate medical structures and
personnel, and to the availability of more sensitive paraclinical
tools which have been included in the new MS diagnostic criteria.
[9–10] As a consequence of this variability, it is very difficult to
aggregate and compare data from different studies. Therefore it is
becoming evident that new epidemiological approaches are
needed to evaluate the changes in incidence and the geographical
distribution of the disease.
The recently proposed ‘‘sex ratio methodology’’ [11] has
opened new perspectives on MS epidemiology. Indeed the
female/male (F/M) sex ratio is a robust epidemiological marker
and can be considered as an internal variable in the same study
groups, thus improving aggregation and comparison of data
collected in different countries and regions. Moreover, confound-
ing effects exerted by differences in time to diagnosis and age of
onset between sexes can be minimized by grouping patients by the
year-of-birth approach. [11–12].
Recent studies designed to investigate change in F/M sex ratio
in MS populations showed an increase over time in several
countries, [11,13–15] regions [16] and cities. [17–18] This
increase mainly affected patients with relapsing onset MS
(RRMS). [17,19] More recent data from other high MS
prevalence areas, such as New Zealand [20] and Tasmania, [21]
have shown sex ratio stability over time.
To date, no study has been designed and conducted in order to
directly compare the sex ratio trends over time among MS
populations from different geographical areas. Difficulties in
uniformly collecting data and handling large different datasets
[22] undoubtedly constitute a major obstacle in such a direction.
The establishment, since July 2004, of the international MSBase
internet platform, [23] with a shared management system, allowed
to overcome at least some of the limitations of regional variability.
The MSBase platform provides an excellent opportunity for
international, collaborative epidemiological studies of MS. On the
basis of the availability of a large dataset, uniformly collected in
this database, through a standardized software system (iMed), we
carried out an exploratory analysis aimed to assess and compare
the significance of year of birth as predictor of sex ratio in MS
populations from different worldwide geographical areas, over a
60-year span. New Zealand data, deriving from a nationwide
prevalence survey conducted in 2006, [20] were also included in
this analysis.
Methods
Cohort Definition and Methods
The MSBase Registry is a strictly observational clinic based
database established in July 2004 for sharing, tracking and
evaluating outcomes data in MS. Investigators aim to include
either all patients or all newly diagnosed patients into the database.
Data are collected in each participating center by a standardized
database management system (iMed). Anonymised datasets are
periodically uploaded to the MSBase server. Objectives, methods
and details of the MSBase project have previously been described.
[23] Data for the current analysis were extracted from the
international MSBase registry in April 2009 and additional data
were provided by the New Zealand MS database. [20] The New
Zealand data comes from a national prevalence survey, with data
validation from treating neurologists. Although both datasets are
collected with different methodologies, accurate recording of year
of symptom onset and sex occur in both, so that combination of
the datasets is reasonable for the current analysis.
A cohort of 15,996 (F = 11,290; M=4,706) patients with a
definite MS according to Poser, [24] McDonald or Polman criteria
[9–10] and with birth years ranging from 1930 to 1989, was
selected. Patients born before 1930 and after 1989 were not
included in the study because the number of patients was
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comparatively small. The mean numbers of women and men by
year of birth (yob) were averaged over 10-year blocks to calculate
the sex ratio. Each block included a mean of 2,658 cases.
Mean age at onset, mean time from onset to diagnosis and
frequency of mono-symptomatic or poly-symptomatic onset were
evaluated according to sex.
Sex ratio trends were analyzed in the whole MS sample and,
separately, after a stratification by geographical areas. A compar-
ison among data from three large groups of countries belonging to
different latitudes (northern area from 83u N and 45u N ,
intermediate area from 45u N to 35u N and southern area from
12u S and 55u S) and, in the smaller European subgroup, between
Northern and Southern countries was performed. A complete list
of countries which provided at least 100 cases is shown in Table 1.
Analyses of gender ratio trends were carried out also after a
stratification of patients by RR or primary progressive (PP) initial
clinical course.
Patient Consent and Ethics
Ethics Committee approval and written signed informed
consent from patients were required and obtained for participation
at each contributing centre.
Statistical Analyses
The mean age at onset and the mean time from onset to
diagnosis in different groups of patients were compared using the
Mann-Withney U test.
The F/M ratios were calculated using a multivariate logistic
regression, per six decades by the yob approach. To avoid a
potential bias from gender disequilibrium at birth, ratios were
adjusted for the F/M born-alive ratio (bar) derived from National
Registries of births in the respective native Countries. In
particular, the true proportion (Py) of women with MS born in
each year (y) was modeled as: ln[Py/(1– Py)] = bintercept+-
b1[yob]+b2[bar]. With each year of birth the F/M ratio increased
by a factor of eb1[yob]. All the analyses were performed using the
Statistical Analysis System (SAS) Package, Release 9.1.
Results
Table 2 shows the distribution of patients by 10-year intervals
based on year of birth. F/M ratio showed a progressive increase
from the first to the last decade (from 2.35 to 2.73; p-value for
trend= 0.032) by a factor (eb1[yob]) of 1.003 with each year of
birth. The frequency of RR course was significantly ( p,0?05)
higher and the mean age at onset was significantly (p,0?05) earlier
in female than in male patients in all the decades examined. The
mean time from onset to diagnosis declined during the six decades
under evaluation (p,0?001) in both female (from 8.96 to 1.69
years) and male ( from 8.74 to 1.78 years) patients, but it did not
differ between sexes in the whole cohort and in the single decades
examined (Table 2). Similar trends of F/M ratio, age at onset, RR
course at onset, time from onset to diagnosis were found in the
three subgroups of patients belonging to northern, intermediate
and southern latitudes (Table 3).
We also assessed the frequencies of mono-symptomatic and
poly-symptomatic onset in female and male patients. The results
showed that they did not differ (p = 0.36) between genders either in
the whole sample (82.2% and 10.7% in females; 88.7% and 11.2%
in males) or in the single decade cohorts examined. Moreover the
time from onset to diagnosis was similar in females and males
belonging to the mono-symptomatic (3.08 6 5.48; 3.15 6 5.58
years, respectively) or poly-symptomatic (4.03 6 6.97; 3.97 6
12.32 years, respectively) groups.
In the analysis by latitude (Fig. 1), the adjusted F/M ratio
showed a progressive increase, through sixty years, from 1.93 to
4.55 (p,0.0001) by a factor (eb1[yob]) of 1.016 with each year of
birth and with an apparent peak of increase after the 1970s, in the
area from 83u N and 45u N. The sex ratio also increased from 1.46
to 2.30 (p,0.05) with a factor (eb1[yob]) of 1.005 with each year
of birth in the area between 45u N and 35u N, whereas no
significant relationship was found between sex ratio and year of
birth at latitudes between 12u S and 55u S where the F/M values
remained steadily high over time (from 3.51 to 2.51; p = 0.355),
The analysis was performed, also, in the subgroup of European
patients (N.7959), separately (Fig.2). A substantial increase of the
F/M ratio from 2.09 to 3.77 (p,0.0004), with an increasing factor
(eb1[yob]) of 1.014 for each year of birth, was found in Northern
Europe (N.2140 patients), whereas only a moderate increase from
1.46 to 2.31 (p,0.05) with an annual factor (eb1[yob]) of 1.005
was shown in Southern Europe (N.5819 patients).
In order to verify the consistency of these results we repeated the
sex ratio analysis by latitude after the exclusion of patients
belonging to the first (1930–1939) and the last (1980–1989) birth
cohorts who could cause a spurious trend in sex ratio mainly
because of younger survival age25 and age at onset in females than
in males. The results paralleled the results of the entire cohort
(Fig 3 A- 3B) confirming a more significant increase in the areas
belonging to northern latitudes both worldwilde (p,0.001) and in
Europe (p = 0.0051).
Finally the sex ratio analysis by latitude was carried out after a
stratification of patients by disease course (RR or PP) at onset in
the countries belonging to northern latitude areas and to Northern
Europe, the results showed that the remarkable increase in ratio
was distributed among patients with a RR course (Fig. 4 A and 4
B). The values ranged from 1.93 to 4.30 (p,0.0001) with an
Table 1. List of Countries with over one hundred cases, divided into three latitude areas.
NORTHERN (836 N - 456 N) CENTRAL (,45oN-35oN) SOUTHERN (126 S - 556 S)
Country n patients Country n patients Country n patients
Belgium 276 France 171 Argentina 706
Canada 1995 Italy 4293 Australia 1664
Germany 151 Portugal 290 New Zealand 2810
Denmark 397 Spain 711
The Netherlands 1316 Turkey 354
TOTAL 4135 TOTAL 5819 TOTAL 5180
doi:10.1371/journal.pone.0048078.t001
Sex Ratio Changes over Time in Multiple Sclerosis
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increasing factor (eb1[yob]) of 1.014 and from 2.11 to 3.52
(p = 0.0016) with an increasing factor (eb1[yob]) of 1.015 in the
global Northern and Northern European samples, respectively. No
change in ratio was observed for patients with PP course in both
samples.
Discussion
We conducted the first direct comparison of the sex ratio trends,
evaluated by a yob approach [11–12] over a 60-year span, among
MS populations from different latitudes. The analysis was
facilitated by the availability of a large international database
with shared demographic and clinical information collection.
Several tests were conducted to identify potential confounders that
could materially influence the results. Firstly, to control for a bias
due to a possible sex disequilibrium at birth, the F/M ratios of MS
patients were adjusted for the F/M born-alive ratios derived from
national birth registries in the respective native participating
countries. Secondly, to exclude that a differential access to
specialized medical care structures for females and males, over
time, in different countries, could be responsible of an apparent
increase of F/M ratio, we calculated the time elapsed from onset
to diagnosis during the six decades under evaluation in the two
sexes. In both female and male groups, time to diagnosis declined
over time, probably explained by the increased awareness of the
disease and new diagnostic tools, [9–10] however this time did not
differ by sex in the different decades examined, indicating that any
changes over time in ascertainment, accessibility to medical
structures and procedures were equally applicable to both sexes
and without significant differences among countries. Similar trends
of F/M ratio, age at onset, RR course at onset, time from onset to
diagnosis were found in the three subgroups of patients belonging
to northern, intermediate and southern latitudes Thirdly, another
potential bias [26] is based on the assumption that milder onset
forms of the disease, potentially more common in females, are
currently more readily diagnosed as MS than in the past, we
investigated whether the frequency of the relatively milder mono-
symptomatic and the more severe poly-symptomatic onset differed
by sex, but no differences were found, suggesting a lack of
diagnostic ascertainment bias on the basis of disease onset severity.
Our results confirm a general, though modest, increase of the
F/M sex ratio (from 2.35 to 2.73) over time among patients
affected by MS, but also show that the rate of increase varies with
latitude. The highest values were observed in countries located in
the most polar latitudes, whereas only a slight increase was
observed in countries of the intermediate latitude, and no increase
in sex ratio was found in countries located at the most southern
latitudes. Similar trends were observed when the analysis was
limited to the smaller European sample.
The consistency of these results was also confirmed when the
analysis was restricted to the four central decades of birth after the
exclusion of the oldest and youngest patients belonging to the first
and last decades who could bias the trend in sex ratio, mainly
because of younger survival age [25] and age at onset in females
than in males and of an heavy-right truncation of the follow-up in
the later birth cohort.
Our findings are consistent with the results from previous
studies conducted in single countries, investigating sex ratio
changes in time spans comparable to those we examined. The
trend of increase (from 1.9 in 1931 to 3.21 in 1980) found in
Canada, [11] in the largest population studied so far, and in Oslo,
Norway, [17] (from 1.48 in 1910 to 2.30 in 1979) is comparable to
our results from all Northern latitude countries (from 1.96 in 1930
to 4.55 in 1989) and from Northern European countries (2.09 in
1930 to 3.77 in 1989). On the other hand, recent studies from New
Zealand [20] and Tasmania [21] found that high F/M sex ratios
remained stable over time (since birth year 1940) as we found on a
larger scale in most equatorial latitude countries where the F/M
Table 2. Sex ratio, percent of relapsing onset, mean age at onset and mean time from onset to diagnosis by birth decades in
female (F) and male (M) MS patients.
Decades
of birth Ratio
Type course
% RR/RR+PPL
by sex Mean Age at onset by sex6
Mean Time from onset
to diagnosis by sex6
F/M* F M F M F M
1930–1939 460/196 73.21 52.021 42.88613.01 44.64611.83 8.96610.62 8.7469.97
2.35
1940–1949 1461/641 79.26 66.841 39.88611.28 41.27610.80 1 7.3268.77 6.4867.54
2.28
1950–1959 2707/1161 89.52 79.501 35.8769.17 36.7168.97 1 5.5766.60 5.5769.11
2.33
1960–1969 3340/1391 94.86 89.781 30.9567.18 31.5467.20 1 3.9464.58 3.6164.42
2.40
1970–1979 2494/1014 97.98 95.18 25.4165.17 25.9664.96 1 2.6063.31 2.4263.28
2.46
1980–1989 828/303 98.95 97.87 19.8263.68 19.6064.21 1.6962.08 1.7862.23
2.73
Total 11290/470606 91.66 84.231 32.03610.24 32.97610.27 1 4.6166.24 4.3966.70
2.41
*15996 pts; p-value for trend 0.032; L14543 pts; u11998 pts; 1 p,0.05 sex M vs. F.
RR=Relapsing remitting; PP = Primary progressive.
doi:10.1371/journal.pone.0048078.t002
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Table 3. Sex ratio, percent of relapsing onset, mean age at onset and mean time from onset to diagnosis by birth decades and
latitude in female (F) and male (M) MS patients.
Northern Latitude
Type course
%
RR/RR+PPL Mean Age at onset by sex6
Mean Time from onset to diagnosis by
sex6
Decade of birth F/M* F M F M F M
1930–1939 87/45 70.27 62.79 43.33613.40 41.38613.83 8.6169.77 9.43611.38
1.93
1940–1949 370/171 75.44 62.73 40.08611.15 41.94610.59 7.4668.36 5.6466.651
2.16
1950–1959 792/327 88.69 79.08 35.6969.31 36.2768.91 5.3966.38 5.2665.78
2.42
1960–1969 932/369 95.65 88.89 30.9267.32 31.7766.94 3.8064.42 3.4664.19
2.53
1970–1979 625/173 97.82 91.19 25.8065.07 26.7764.59 1 2.5863.09 2.1562.68
3.61
1980–1989 200/44 98.93 100.00 20.2463.35 20.3864.68 1.7562.12 2.3262.93
4.55
TOTAL 3006/1129 91.36 81.84 31.9269.91 33.6769.77 1 4.4265.79 4.2565.50
2.66
*4135 pts; p-value for trend 0.0001; 3ˆ877 pts; u3619 pts; 1 p,0.05 sex M vs. F
Latitude
North-Central
Type course
%
RR/RR+PPL Mean Age at onset by sex6
Mean Time from onset to North-
Central
Decade of birth F/M* F M F M F M
1930–1939 89/61 67.47 54.24 46.33612.58 43.20611.12 8.4169.63 9.03610.50
1.46
1940–1949 340/174 76.45 72.02 39.78611.75 40.91612.11 8.3069.59 8.4669.68
1.95
1950–1959 734/382 90.68 82.66 35.2669.05 36.4769.54 6.9467.22 6.2367.23
1.92
1960–1969 1247/579 95.02 91.64 30.5267.23 30.2667.67 4.2064.81 4.2365.12
2.15
1970–1979 1082/534 98.02 97.12 24.9465.49 25.2665.33 2.9263.82 2.6063.73
2.03
1980–1989 416/181 98.54 98.86 19.3563.77 19.2064.20 1.7862.05 1.7562.28
2.30
TOTAL 3908/1911 93.23 89.11 29.6669.82 30.18610.15 4.5165.96 4.4066.16
2.05
*5649 pts; p-value for trend 0.0425; 5ˆ649 pts; u3487pts
Latitude Southern
Type course
%
RR/RR+PPL Mean Age at onset by sex6
Mean Time from onset to diagnosis by
sex6
Decade of birth F/M* F M F M F M
1930–1939 270/77 75.86 43.66 42.08612.90 46.81610.83 1 9.17611.08 8.3069.10
3.51
1940–1949 690/268 82.54 66.03 39.83611.21 41.03610.45 6.9568.67 6.2667.04
2.57
1950–1959 1027/388 89.32 76.74 36.2669.11 37.1768.66 5.1066.39 5.41611.69
2.65
1960–1969 973/355 93.94 87.61 31.3166.98 32.5866.80 1 3.8664.54 3.1563.791
2.74
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ratio remained steadily equal to or higher than 2.5 in all the
analysed decades.
Our results also demonstrate that the global increase of MS
incidence in polar and intermediate latitudes is principally driven,
as previously demonstrated in other studies, by females with
RRMS. [17–19] This increase in MS incidence may result from
an intensification of the effect, in these latitudes, of sex-related
factors, the influence of which seems otherwise unchanged over
time in latitudes where high sex ratio disequilibrium remains
stable. The kind of etiological factor(s) causing increased disease
susceptibility in women can only be speculated upon. [27] Given
the short duration over which sex ratio changes have occurred,
genetic factors are unlikely to be driving this change. [11] It is
more likely that the observed change in sex ratio is due to altered
environmental factors or the result of latitudinally-sensitive gene-
environment interactions. This hypothesis has also been supported
by the results of a recent study [28]showing that the sex ratio in
immigrants to Canada, with post-migration MS onset, is
increasing. The rate of the increase observed in this study was
the highest in immigrants of southern-European origin by a factor
of 1.27 per 10-year period. This rate of increase was higher than
that which we found in the MS population born and resident in
southern European countries (annual factor of 1.005), suggesting
that moving to Canada increases MS risk in women of southern
European origin.
However, latitudinal effects cannot uniquely explain regional
variation in female MS incidence. Interestingly, a remarkable
increase in the sex ratio was found in Isfahan, [18] an Iranian
province approximately located on the border between the
northern and intermediate latitude areas, as defined in our study,
where minimal, if any, increase in sex ratio could be expected on
the basis of our results. These results suggest that latitudinal
Table 3. Cont.
Latitude Southern
Type course
%
RR/RR+PPL Mean Age at onset by sex6
Mean Time from onset to diagnosis by
sex6
Decade of birth F/M* F M F M F M
1970–1979 651/246 98.08 93.56 25.6064.83 26.4564.48 1 2.2762.82 2.3462.90
2.65
1980–1989 168/67 100.00 93.65 20.2663.79 19.8663.86 1.4162.06 1.4761.41
2.51
TOTAL 3779/1401 90.26 79.36 33.69610.44 34.81610.24 1 4.8166.72 4.4967.84
2.70
*5180 pts; 5ˆ017 pts; u4892 pts; 1 p,0.05 sex M vs. F
RR=Relapsing remitting; PP = Primary progressive.
doi:10.1371/journal.pone.0048078.t003
Figure 1. Plot of gender ratio by six birth decades in MS patients stratified by Latitude. p-value for trend *0.0425; **,0.0001.
doi:10.1371/journal.pone.0048078.g001
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variations of disease frequency may be modified by the effect of
other concurrent risk factors (ethnic, cultural and socio-economic).
There is growing evidence that solar ultraviolet radiation (UV)
exposure, which varies with latitude, is associated with vitamin D
biological activity and sex in contributing to the risk of MS [29–
31] and higher sunlight exposure before the age of 15 has been
associated with a decreased risk of MS. [32] In a study carried out
in the province of Isfahan, [33] the prevalence of severe vitamin D
deficiency (,8 ng/ml) in winter was significantly higher in high
school-age girls than in boys. The 1,25-dihydroxyvitamin D3 or
calcitriol has a well recognized modulating effect on the adaptive
immune system and particularly on T cell homeostasis. [34]
Immunomodulation exerted by calcitriol seems to be biased
towards female sex in its protective effect both in the experimental
animal model of MS [35] and in MS patients. [36–37] A dose-
dependent and linear correlation between increasing levels of
vitamin D and reduced hazard of relapse in people with RR-MS
was recently reported [38] and a synergism between 17b estradiol
and vitamin D3, leading to an increased anti-inflammatory and
protective effect of vitamin D3 in women, [37] has also been
demonstrated.
Figure 2. Plot of gender ratio by six birth decades in MS patients from Northern and Southern Europe. p-value for trend *0.0426;
**,0.0004.
doi:10.1371/journal.pone.0048078.g002
Figure 3. Plot of gender ratio by four birth decades in MS patients stratified by Latitude (A) and from Northern and Southern
Europe (B). p-value for trend *,0.001.
doi:10.1371/journal.pone.0048078.g003
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Even more intriguing is the fact that solar exposure is not only
related to latitude but also to cultural and social aspects. Studies
carried out in countries with Islamic tradition have shown that
vitamin D deficiency is more common in veiled women. [39]
Vitamin D serum levels also depend on alimentary intake, again
an extremely variable element either among different countries as
among single individuals. Furthermore changes in other environ-
mental risk factors for MS such as smoking behaviour [40–41] and
infections [42] could interact with physiological differences
between genders, such as sex steroids or sex-related gene-
expression and epigenetic regulation, converging together with
Vitamin D activity, on molecular immunological and inflamma-
tory mechanisms that have been shown to have a sex bias. [43–45]
This quite complex congregation of variables could well account
for exceptions that can be found to the latitudinal gradient
principle.
It seems likely, ultimately, that latitudinal, genetic and local
environmental factors interact to cause MS, and our study
confirms that the latitudinal effects are becoming more relevant
at polar and intermediate latitudes for the RR phenotype in
women.
In conclusion this exploratory analysis on the geographical
variations in sex ratio trends over time in MS does not claim to
have the strength of a global population-based study, nevertheless
some significant remarks can be drawn from the results. First, our
findings encourage further use of the MS sex ratio methodology, to
reappraise its trend in the next years on a prospective basis and to
validate its relationship with more traditional epidemiological
measures such as incidence and prevalence. Second, the demon-
stration of an uneven distribution of sex ratio time-trends among
populations from different geographical areas, derived by a direct
comparison of uniformly collected data in an international
database, adds useful information for planning studies aimed to
explore the paths of aetiological hypotheses about MS, primarily
the role of Vitamin D. This should be effectively done both by
case-control studies as well as by focused bench and in vivo
research. The mergence of both these epidemiological ‘‘top-down’’
and laboratory ‘‘bottom-up’’ approaches could return huge
clinical advantages enhancing prevention and treatment of MS.
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